1 week ago
4
Soumya Eswaran
Wed, December 24, 2025 astatine 7:02 AM CST 3 min read
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Hedged Equity Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. In the quarter, the marketplace is much focused connected the tailwind of argumentation easing than the headwind of weakening fundamentals, resulting successful important gains contempt stagflation emerging arsenic a cardinal concern. In this environment, the money returned 1.67% (net) during the quarter, compared to 8.13% returns of the S&P 500 Index and 3.53% returns of the secondary benchmark, the CBOE S&P 500 BuyWrite Index. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.
In its third-quarter 2025 capitalist letter, Meridian Hedged Equity Fund highlighted stocks specified arsenic Johnson & Johnson (NYSE:JNJ). Johnson & Johnson (NYSE:JNJ) is simply a multinational institution that engages successful the research, development, and manufacturing of products successful the healthcare field. The one-month instrumentality of Johnson & Johnson (NYSE:JNJ) was -0.43%, and its shares gained 41.09% of their worth implicit the past 52 weeks. On December 23, 2025, Johnson & Johnson (NYSE:JNJ) banal closed astatine $205.78 per share, with a marketplace capitalization of $495.785 billion.
Meridian Hedged Equity Fund stated the pursuing regarding Johnson & Johnson (NYSE:JNJ) successful its 3rd 4th 2025 capitalist letter:
"Johnson & Johnson (NYSE:JNJ) is simply a large healthcare institution focused connected innovative pharmaceuticals and aesculapian devices. The institution faces a captious modulation arsenic income from its blockbuster cause Stelara statesman to diminution owed to patent expiration. However, J&J is successfully executing connected its strategy to offset these losses with a robust pipeline of caller drugs, peculiarly successful oncology and immunology. The banal responded positively successful the 4th arsenic the institution demonstrated important advancement connected aggregate fronts. It secured a landmark FDA support for Inlexzo, a caller bladder crab attraction with important income potential, and its lung crab cause Rybrevant moved person to broader adoption aft receiving affirmative proceedings information for a much convenient injection format. Strong income momentum crossed different cardinal drugs much than compensated for Stelara's decline, portion favorable ineligible developments eased capitalist concerns astir the company's ongoing talc litigation."
Johnson & Johnson (NYSE:JNJ) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 103 hedge money portfolios held Johnson & Johnson (NYSE:JNJ) astatine the extremity of the 3rd quarter, up from 95 successful the erstwhile quarter. While we admit the imaginable of Johnson & Johnson (NYSE:JNJ) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.
English (CA) · 
English (US) · 
Spanish (MX) ·